ISOO 2022: Dr. Shields Presents Phase 1b/2 IVT AU-011 Data

A Phase 1b/2 Trial of belzupacap sarotalocan (AU-011), a First-in-Class Targeted Therapy for the Treatment of Choroidal Melanoma via Intravitreal Administration